Immix Biopharma closed a $140.65 million public offering, focusing on AL Amyloidosis treatment, involving major biotech investors.
Quiver AI Summary
Immix Biopharma, Inc. has successfully completed an underwritten registered offering of 16,778,524 shares of its common stock at a price of $8.94 per share, generating approximately $140.65 million in net proceeds. The financing involved significant participation from leading U.S. biotechnology institutional investors and mutual funds, with Morgan Stanley serving as the lead book-running manager. The offering was conducted under an effective shelf registration statement filed with the SEC. ImmixBio, a leader in the treatment of AL Amyloidosis, is currently advancing its lead CAR-T cell therapy candidate, NXC-201, which aims to combat the disease by targeting toxic light chains responsible for organ failure. This therapy has received multiple designations from the FDA and EMA, including Breakthrough Therapy Designation.
Potential Positives
- Immix Biopharma successfully raised approximately $140.65 million from the offering, strengthening its financial position for further development initiatives.
- The financing involved leading U.S. biotechnology institutional investors and mutual funds, indicating significant confidence in the company's future prospects.
- The company’s lead candidate, NXC-201, has received Breakthrough Therapy Designation and other important FDA designations, highlighting its potential impact in treating AL Amyloidosis.
Potential Negatives
- The press release does not provide information on the use of proceeds from the offering, which may raise concerns among investors about the company's financial strategy and transparency.
- The issuance of new shares could dilute existing shareholders' equity, potentially leading to dissatisfaction among current investors.
- While the press release highlights participation from leading U.S. biotechnology institutional investors, it may also imply that the company needed substantial external financing, suggesting possible challenges in achieving self-sustaining operations.
FAQ
What is the total amount raised by Immix Biopharma in the stock offering?
Immix Biopharma raised approximately $140.65 million from its underwritten registered offering.
Who were the lead managers for the stock offering?
Morgan Stanley acted as the lead book-running manager, with BofA Securities as the book-running manager.
What is the main focus of Immix Biopharma?
Immix Biopharma is a global leader in treating AL Amyloidosis, a serious disease affecting organ function.
What is the purpose of the NXC-201 therapy developed by Immix Biopharma?
NXC-201 is designed to help the immune system recognize and eliminate toxic light chains causing AL Amyloidosis.
What designations has NXC-201 received from the FDA?
NXC-201 has received Breakthrough Therapy Designation, Regenerative Medicine Advanced Therapy designation, and Orphan Drug Designation from the FDA.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IMMX Insider Trading Activity
$IMMX insiders have traded $IMMX stock on the open market 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IMMX stock by insiders over the last 6 months:
- GABRIEL S MORRIS (CFO) purchased 770 shares for an estimated $5,066
- ILYA M RACHMAN (CEO and Chairman) purchased 746 shares for an estimated $4,975
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
$IMMX Hedge Fund Activity
We have seen 51 institutional investors add shares of $IMMX stock to their portfolio, and 26 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JANUS HENDERSON GROUP PLC added 3,921,568 shares (+inf%) to their portfolio in Q4 2025, for an estimated $20,509,800
- VELAN CAPITAL INVESTMENT MANAGEMENT LP added 705,000 shares (+2014.3%) to their portfolio in Q1 2026, for an estimated $6,422,550
- SATURN V CAPITAL MANAGEMENT LP added 694,416 shares (+23.2%) to their portfolio in Q1 2026, for an estimated $6,326,129
- AMERIPRISE FINANCIAL INC removed 452,147 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $4,119,059
- BLUE OWL CAPITAL HOLDINGS LP removed 438,688 shares (-44.5%) from their portfolio in Q1 2026, for an estimated $3,996,447
- PRICE T ROWE ASSOCIATES INC /MD/ added 415,001 shares (+inf%) to their portfolio in Q1 2026, for an estimated $3,780,659
- VANGUARD GROUP INC added 365,652 shares (+50.1%) to their portfolio in Q4 2025, for an estimated $1,912,359
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
$IMMX Price Targets
Multiple analysts have issued price targets for $IMMX recently. We have seen 5 analysts offer price targets for $IMMX in the last 6 months, with a median target of $20.0.
Here are some recent targets:
- Robert Burns from HC Wainwright & Co. set a target price of $20.0 on 05/22/2026
- Graig Suvannavejh from Mizuho set a target price of $15.0 on 03/30/2026
- Reni J. Benjamin from Citizens set a target price of $23.0 on 03/27/2026
- Judah Frommer from Morgan Stanley set a target price of $20.0 on 03/25/2026
Full Release
– Financing includes leading U.S. biotechnology institutional investors and mutual funds –
LOS ANGELES, CA, May 22, 2026 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us” or “IMMX”), a global leader in AL Amyloidosis, today announced the closing of its previously announced underwritten registered offering of 16,778,524 shares of its common stock at a price to the public of $8.94 per share. The net proceeds to Immix from the offering, after deducting the underwriting discounts, commissions and other offering expenses, were approximately $140.65 million.
The financing includes leading U.S. biotechnology institutional investors and mutual funds.
Morgan Stanley acted as the lead book-running manager and BofA Securities acted as book-running manager for the offering. LifeSci Capital, Mizuho and Needham & Company acted as co-lead managers for the offering.
The securities in the registered offering were offered and sold pursuant to a “shelf” registration statement on Form S-3 (File No. 333-292665), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on January 9, 2026, and declared effective on January 22, 2026. A prospectus supplement and accompanying prospectus describing the terms of the registered offering was filed with the SEC and is available on its website at www.sec.gov. Copies of the prospectus supplement and the accompanying prospectus relating to the offering may also be obtained from: Morgan Stanley & Co. LLC, attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, New York 10014, by phone: 1-866-718-1649 or by email: [email protected] .
This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Immix Biopharma, Inc.
Immix Biopharma, Inc. (ImmixBio) (Nasdaq: IMMX) is a global leader in AL Amyloidosis. AL Amyloidosis is a devastating disease where the immune system, that’s supposed to protect, instead produces toxic light chains, clogging up the heart, kidney and liver, causing organ failure and death. Our lead candidate is sterically-optimized BCMA-targeted chimeric antigen receptor T (CAR-T) cell therapy NXC-201 with a “digital filter” that is designed to filter out non-specific activation. NXC-201 teaches the immune system to recognize and eliminate the source of the toxic light chains. NXC-201 is being evaluated in the U.S. multi-center study for relapsed/refractory AL Amyloidosis NEXICART-2 (NCT06097832), with a potentially registrational design. NXC-201 has been awarded Breakthrough Therapy Designation (BTD) and Regenerative Medicine Advanced Therapy (RMAT) by the US FDA and Orphan Drug Designation (ODD) by FDA and in the EU by the EMA.
Contacts
Mike Moyer
LifeSci Advisors
[email protected]
Company Contact
Gabriel Morris, CFO
[email protected]
